The exercise of warrants provides Aptevo with additional capital, which can be used to further its clinical-stage biotechnology projects. The reduced exercise price may indicate a strategic move to encourage warrant holders to convert, thus strengthening the company's financial position. This is likely to have a positive short-term impact on the stock price as it reflects investor confidence and provides the company with necessary funds.